Helen S. Jung

A woman standing outdoors on a dirt trail in a mountainous forest with pine trees, cacti, and a clear blue sky.

Keywords: antibody dependent enhancement, flavivirus, Zika, dengue, EDIII, NS1, B cell response, vaccine, immunogen, phage display, recombinant expression, FACS

Dengue and Zika viruses are mosquito-transmitted flaviviruses that cause severe, fatal disease in patients with history of previous infection by these viruses. Despite the growing population of at-risk communities because of globalization and climate change, there is still a need for vaccines and anti-viral therapies without the complication of enhancing disease severity. To address this need, I investigate structure-based designs of broadly protective vaccines that are effective against both viruses using techniques to focus the adaptive immune system to neutralizing, protective antibody response. I have additional secondary projects in the lab which involve antibody and immunogen engineering.

I have worked on a variety of different projects before joining the Lai Lab. In Dr. Robert Fairman's lab at Haverford College, I studied polymerizing systems to develop nano-biomaterials with various biophysical functions. I designed a protein nanowire system based on a pilin protein naturally occurring in bacteria. I characterized in vitro conductivity of the protein system as well as its functionalization with photoelectronic compounds to achieve photoconductive properties. In Dr. Paul Axelsen’s lab at the University of Pennsylvania, I applied the reverse micelle model to study amyloid-beta protein and Alzheimer’s disease. I also characterized biophysical properties of reverse micelle systems and spectroscopically examined their nanoscale pH-profiles. In Dr. Leena Hilakivi-Clarke's lab at Georgetown University, I studied transgenerational effects of maternal exposures, such as high-fat diet, on the risk of breast cancer occurrence and severity in F2 and F3 progeny. I used preclinical rodent models to evaluate changes in DNA methylation patterns of oncogenes.

I'm a senior board member of the AECOM Women's Networking Group. We organize monthly events, such as docu-screenings, summer socials, and science-themed game events, as well as annually host Women in Science Day, one of the largest club events on campus. We're a collective of grad students, postdocs, and faculty members aiming to foster a community of women scientists. Apart from WNG, I help out with the weekend food markets organized by City Harvest when I can! I enjoy rock climbing and taking dance classes, and I also play music and sing with my friends in our cover band.

I am actively seeking to connect with physician-scientists in innovative, evolving medical specialties as well as professionals in therapeutics development. If you're a student at any level of training or education who is interested in my training path, feel free to reach out!


Previous Education

Haverford College, 2018 - B.S. in Biology

Albert Einstein College of Medicine - MSTP

Highlights

  • Publication: Georgiev, G.I.; Malonis, R.J.; Wirchnianski, A.S.; Wessel, A.W.; Jung, H.S.; Cahill, S.M.; Nyakatura, E.K.; Vergnolle, O.; Dowd, K.A.; Cowburn, D.; Pierson, T.C.; Diamond, M.S.; Lai, J.R. 2022. Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses in vivo. Cell Chem. Biol.

  • Award: Top Presentation Prize. Gordon Research Conference for the Chemistry and Biology of Peptides. 2022. Korean American Scholarship Foundation (KASF) Medical Student Scholarship. 2018. Clinical and Translational Sciences Award (CTSA). Perelman School of Medicine. 2017.

  • Presentation: Gordon Research Conference for the Chemistry and Biology of Peptides. Investigating heterotypic nanoparticle formats for immunoprotection across infections by Zika and dengue viruses. 2022. 6th Annual Biomedical Research Graduate Student Symposium, City of Hope. Investigating heterotypic nanoparticle formats for immunoprotection across infections by Zika and dengue viruses. 2022. American Chemical Society Fall Symposium. Strategies for next-generation flavivirus vaccine development. 2022.